Given its prevalence and potential as a therapeutic target, particularly in NSCLC, mutant-specific KRAS G12C inhibitors such as MRTX849 (adagrasib) and AMG 510 (sotorasib) have emerged as promising therapeutic agents, demonstrating efficacy in treating KRAS G12C-driven malignancies [9]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.